Minty Bets is joined by Kevin Iole to discuss the WBO Welterweight Title Bout between Terence Crawford vs. Kell Brook this Saturday November 14.
Minty Bets is joined by Kevin Iole to discuss the WBO Welterweight Title Bout between Terence Crawford vs. Kell Brook this Saturday November 14.
Australian singer Sia's movie directing debut is coming under fire over its representation of autism, and for her choice to use an actress without autism in the lead role.
Meghan has opened up about a miscarriage she suffered in July.
For today's agenda, Mr. Xiao will provide an overview of our recent performance and highlights; Mr. Zeng will discuss our financial results; and Mr. Liu will discuss our credit performance. Thank you, everyone.
SJM earnings call for the period ending September 30, 2020.
JWN earnings call for the period ending September 30, 2020.
The incident occurred at approximately 7:39 p.m. in the South Los Angeles neighborhood of Florence when 50-year-old Jose Fuentes was crossing a street when a motorcycle traveling northbound collided with him, according to the Los Angeles Police Department. In video released by the LAPD, Fuentes can be seen lying in the road after being struck by the motorcycle as it speeds away. Just seconds later Fuentes is then hit by a white sedan which also fled the scene after the collision, according to ABC News’ Los Angeles station KABC.
The "European Heat Pump Market and Statistics Report 2020" report has been added to ResearchAndMarkets.com's offering.
You won’t want to miss out
lululemon athletica inc. (NASDAQ: LULU) today announced that its financial results for the third quarter fiscal 2020 will be released Thursday, December 10, 2020. The company will host a conference call at 4:30 p.m. Eastern time to discuss the financial results.
Black Friday Breville Smart Oven Air deals are underway, check out all the latest Black Friday Breville toaster and air fryer oven sales right here on this page Black Friday Breville Smart Oven Air deals are underway. Review the top savings on best-selling Breville air fryer and toaster ovens. Links to the best deals are listed below. Best Breville Smart Oven Deals: * Save up to 20% on Breville Smart Oven Air & Smart Ovens at Breville.com * Save up to 36% on Breville smart ovens & toaster ovens at Amazon \- check live prices on Breville air ovens & smart ovens including best-selling BOV845BSS & BOV800XL smart ovens * Save up to 40% on a wide range of Breville smart ovens at Walmart \- check the latest deals on Breville’s top-selling Smart Oven Pro, Mini Smart Oven, Compact Smart Oven, and more Best Breville Deals: * Save up to 20% on Breville espresso machines, smart ovens & more at Breville.com \- plus enjoy free shipping on all orders * Save up to 30% on a wide range of Breville smart ovens, espresso machines & more at Walmart \- check the latest deals on Breville smart ovens, toaster ovens, Barista Express, Nespresso machines & more * Save up to 40% on Breville kitchen appliances at Amazon \- check live prices on the top-selling Smart Oven Air, Sous Chef food processors & Breville Vertuo Nespresso machines, Barista Express, and more Best Oven Deals: * Save up to 50% on ovens from Ninja, Hamilton Beach, Cuisinart, Best Choice & more at Walmart \- check the latest deals on smart ovens, toaster ovens, air fryer ovens, convection ovens, and more * Save up to 40% on ovens from Breville, Cuisinart, and Ninja at Amazon \- check live prices on best-selling convection ovens, air fryer ovens, and smart ovens * Save up to 20% on Breville Smart Oven Air & Smart Ovens at Breville.com * Save up to 31% on ovens from Cuisinart, BLACK+DECKER and KitchenAid at Target.com \- check the latest savings on digital countertop ovens, toaster ovens, air fryer ovens, and more * Save up to 67% on a wide range of air fryer ovens at Walmart \- check the latest deals on air fryer ovens from Ninja, Cuisinart, Hamilton, and more Searching for more deals? Click here to check out the full range of active deals at Walmart’s Black Friday Deals for Days sale and click here to check out Amazon’s current Black Friday deals. Save Bubble earns commissions from purchases made using the links provided.About Save Bubble: Save Bubble round-up the latest online sales news. As an Amazon Associate and affiliate Save Bubble earns from qualifying purchases.Contact: Andy Mathews (firstname.lastname@example.org)
LA JOLLA, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) were published in Multiple Sclerosis Journal. OCT was a secondary outcome measure in the SPRINT-MS trial. The publication, entitled “Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis”, is a report of the OCT results of the SPRINT-MS trial. The authors include Robert A. Bermel and Robert J. Fox, both from the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic, and several others. The authors conclude that retinal thinning in MS may be attenuated by MN-166 (ibudilast) and that sample size estimates suggest OCT can be a viable outcome measure in progressive MS trials if a therapy has a large treatment effect.Of the 28 sites participating in the SPRINT-MS trial, 22 sites used Zeiss Cirrus OCT and 6 sites used Heidelberg Spectralis OCT. This resulted in 183 participants imaged with Cirrus and 61 participants imaged with Spectralis.All OCT measures showed less loss of retinal tissue for MN-166 (ibudilast) compared to placebo. Key results reported in the publication include the following: * Change in pRNFL (peripapillary retinal nerve fiber layer) thickness was +0.0424 uM/year for MN166 (ibudilast) versus −0.2630 uM/year for placebo (n = 244, p = 0.22). * Macular volume change was −0.00503 mm3/year for MN-166 (ibudilast) versus −0.03659 mm3/year for placebo in the Spectralis cohort (n = 61, p = 0.044). * For the Cirrus cohort, macular volume change was −0.00040 mm3/year for MN-166 (ibudilast) compared to −0.02083 mm3/year for placebo (n = 183, p = 0.1734). * Ganglion cell-inner plexiform (GCIP) layer thickness change, available from Cirrus, was −0.4893 uM/year for MN-166 (ibudilast) versus −0.9587 uM/year for placebo (n = 183, p = 0.12).Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc. commented, “We are very pleased that the positive OCT data has been published. This data demonstrates that MN-166 can reduce retinal thinning in progressive MS patients and is further evidence of its neuroprotective effect as retinal thinning is associated with brain volume loss and other measures of MS progression.”About the Progressive MS TrialThe Phase 2b Secondary and Primary Progressive Ibudilast NeuroNEXT trial in Multiple Sclerosis (SPRINT-MS) included 28 enrolling clinical sites across the U.S. and was designed to evaluate the safety, tolerability and activity of MN-166 (ibudilast) administered orally twice daily to subjects with primary progressive or secondary progressive multiple sclerosis (PPMS or SPMS, respectively). 255 qualifying subjects were randomly assigned 1:1 to inactive control (placebo) or MN-166 (ibudilast) administered at a dose of up to 100 mg/day (50 mg twice daily). The progressive MS subjects were either untreated with long-term disease modifying therapy (DMT) or continued on either glatiramer acetate (GA) or interferon beta (IFNβ-1a or IFNβ-1b) treatment. Hence, randomization was controlled (stratified) by two factors: therapy status (IFN/GA vs. no DMT) and disease status (PPMS vs. SPMS). The primary objectives of the study were to 1) evaluate the activity of ibudilast (MN-166) versus placebo at 96 weeks as measured by quantitative magnetic resonance imaging (MRI) analysis for whole brain atrophy using brain parenchymal fraction (BPF), and 2) evaluate the safety and tolerability of ibudilast (MN-166) versus placebo in subjects with PPMS or SPMS. Additional measures included disability, imaging analyses of brain and retinal tissue integrity, cortical atrophy, cognitive impairment, quality-of-life and neuropathic pain. Exploratory objectives included pharmacokinetic and biomarker analyses.About the Cooperative EffortThe collaborating entities included NeuroNEXT, the Cleveland Clinic, the National MS Society and MediciNova. NINDS's Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations and industry. NeuroNEXT sites include many of the leading medical centers in the U.S. (www.neuronext.org). The goals of NeuroNEXT include testing of promising neurological therapies in Phase 2 clinical trials, optimizing drug development time and cost components through an established clinical trials infrastructure, and the coordination of public/private sector efforts by leveraging NINDS’s existing relationships with academic investigators and patient advocacy groups. A clinical coordinating center for NeuroNEXT was led by Dr. Merit Cudkowicz and was based at Massachusetts General Hospital and the data coordinating center was led by Dr. Chris Coffey at the University of Iowa. Principal Investigator Dr. Robert Fox and colleagues at the Cleveland Clinic collaborated with co-investigators at academic medical centers in the NeuroNEXT network. The National MS Society provided patient advocate input, trial enrollment awareness, and additional funding. MediciNova holds the trial IND with the FDA’s Division of Neurology Products and provided scientific and analytical support, as well as drug and placebo supply.About Progressive Multiple SclerosisAccording to the National MS Society, MS affects approximately 2.3 million people worldwide. Approximately 85% of MS patients are initially diagnosed with relapsing remitting MS (RRMS). Many RRMS patients will eventually transition into secondary progressive MS (SPMS) in which there are fewer or no relapses but gradual worsening of neurologic function. Approximately 15% of MS patients are diagnosed with primary progressive MS (PPMS) at onset and exhibit gradually increasing disability in walking, vision, mental acuity, and other bodily functions without experiencing relapses or remissions. Current therapies for MS affect the inflammatory response, but provide limited benefit for the neurodegeneration seen in progressive MS. There is a significant unmet medical need for agents that may provide neuroprotection in progressive MS. About MN-166 (ibudilast) MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. Our earlier human studies demonstrated significant reductions of serum MIF level after treatment with MN-166 (ibudilast). It also attenuates activated glial cells, which play a major role in certain neurological conditions. MN-166 (ibudilast)'s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical studies, which provide the rationale for treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS) and other neurological diseases such as glioblastoma (GBM), and substance abuse/addiction. MediciNova is developing MN-166 for ALS, progressive MS and other neurological conditions such as degenerative cervical myelopathy (DCM), glioblastoma, substance abuse/addiction, and chemotherapy-induced peripheral neuropathy, as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19. MediciNova has a portfolio of patents which covers the use of MN-166 (ibudilast) to treat various diseases including ALS, progressive MS, and drug addiction.About MediciNovaMediciNova, Inc. is a publicly traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on BC-PIV SARS-COV-2 vaccine for COVID-19, MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin). For more information on MediciNova, Inc., please visit www.medicinova.com.Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.INVESTOR CONTACT: Geoff O'Brien Vice President MediciNova, Inc. email@example.com
Black Friday Roomba 675 & 690 deals have landed, check out all the best Black Friday bundles, accessories & more deals below Black Friday 2020 sales researchers are identifying all the latest Roomba 675 & 690 deals for Black Friday 2020, including the best offers on Roomba 675 & 690 bundles, accessory kits and more. Check out the full selection of deals in the list below.Best Roomba 675 & 690 Deals: * Save up to $86 on Roomba 600 series robot vacuums at Walmart \- check the latest deals on Roomba 690, 675, 670, 650 & more top-rated entry level Roomba models * Save up to 31% on iRobot Roomba 675 & more Roomba 600 series robot vacuums at Amazon \- click the link to see the latest deals including discounts on bundles and accessory kits * Save on the iRobot Roomba 675 at iRobot.com \- check the latest deal on this WiFi-connected robot vacuum that works with Google Home and Alexa-enabled devices * Save on the iRobot Roomba 690 robot vacuum at Amazon \- check live prices on this Wi-Fi connected robot vacuum that is self-charging and can be used on both carpets or hard floors * Save on the iRobot Roomba 690 robot vacuum cleaner at Amazon \- includes deals on Roomba 690 replacement parts, accessories, and decals in different colors and designsBest Roomba Deals: * Save up to $400 on a wide range of Roomba robot vacuum bundles & deals at Walmart \- check deals available on the Roomba 980, 960, 690, Braava jet M6 and more new and refurbished models * Save up to $200 on iRobot Roomba robot vacuums at Amazon \- check deals on the best-selling iRobot Roomba 960, s9, i7, i7+, 650 and e5 models * Save up to $200 on Roomba robot vacuums & robot mops at Target \- save on iRobot smart cleaning products including the Roomba 675, e5, Braava Jet 230 robot mop & more * Save up to $380 on select Roomba robot vacuums & bundle deals at iRobot.com \- save on the Roomba 960, e5, 675 & more top-rated models and Braava robot mops * Save up to $100 on Roomba Braava mops at iRobot.com \- check out iRobot deals on the Braava jet m6, 380t & jet 240 models * Save on the iRobot Braava jet M6 robot mop at Amazon \- the M6 tackles sticky messes, grime, and kitchen grease with ease (limited time deal) * Save up to $100 on the iRobot Braava intelligent robot mop at Walmart \- check live prices on iRobot Braava models including the Jet M6 that works with Google Home and is ideal for multiple rooms In need of some more deals? Click here to compare the full selection of live deals at Walmart’s Black Friday sale and click here to see Amazon’s live Black Friday deals. The Consumer Post earns commissions from purchases made using the links provided.About The Consumer Post: The Consumer Post shares news for online shoppers. As an Amazon Associate and affiliate The Consumer Post earns from qualifying purchases.Contact: Andy Mathews (firstname.lastname@example.org)
Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional CountriesCAMBRIDGE, Mass. and ROSTOCK, Germany and HEIDELBERG, Germany and BERLIN, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has expanded its partnership with PTC Therapeutics, Inc. The companies will work together in several new regions including many countries in Europe, the Middle East, and Latin America to provide genetic testing and 3-O-Methyldopa (3-OMD) biomarker analytics to help identify patients with Aromatic L-amino Acid Decarboxylase (AADC) deficiency. AADC deficiency is a life-shortening, ultra-rare genetic disorder that causes severe disability and ongoing physical and mental suffering from the first few months of life. In addition, CENTOGENE will now provide this testing and biomarker analytics for patients involved in the REVEAL CP study, a screening study designed to determine the prevalence of AADC deficiency in patients with cerebral palsy (CP) of unknown cause. The REVEAL CP study will screen patients for AADC deficiency with CentoCard® – CENTOGENE’s CE-labeled dried blood spot collection kit – by evaluating blood samples for above normal levels of 3-OMD. Patients with elevated 3-OMD will be further tested for decreased levels of AADC enzyme activity and the presence of variants in the DOPA decarboxylase (DDC) gene. Through the generation of insights from the study, CENTOGENE and PTC aim to shorten the diagnosis time for patients living with AADC deficiency and ultimately accelerate the discovery of potential treatment options for patients living with this rare genetic disorder.Justin Bingham, CENTOGENE’s Senior Vice President of Business Development, stated, “We are pleased to expand our partnership with PTC to support the REVEAL CP study, a global screening study designed to determine the prevalence of AADC deficiency in patients with cerebral palsy of an unknown cause. Together, we will offer genetic testing and 3-OMD biomarker analytics and widen the geographical scope of the no cost testing program, all of which are critical steps as we work together to bring hope to patients living with this rare genetic disorder.”“PTC is proud to continue and expand our partnership with CENTOGENE. We believe the insights we expect to gain from this genetic testing program may help physicians diagnose patients with AADC deficiency,” said Claudio Santos, Senior Vice President of Global Medical Affairs at PTC Therapeutics. “The AADC deficiency diagnostic testing program and REVEAL CP study are critical ways in which we can help to shorten the diagnostic journey that so many patients and families face. This is central to our mission and daily commitment at PTC to help patients with rare disorders.”CENTOGENE and PTC began collaborating in 2019 to create a diagnostic program for AADC deficiency, a rare inherited disorder that affects the way signals are passed between certain cells in the nervous system. AADC deficiency causes severe developmental disabilities, the inability to develop any motor strength and control, frequent hospitalizations, and the need for life-long care. At this time, there is no cure for AADC deficiency.The testing is provided at no cost to patients and can be accessed via CENTOGENE’s user-friendly CentoPortal® platform (www.centoportal.com), or alternatively by sending an email to AADCdtesting@ptcbio.com. To learn more about the REVEAL CP study email email@example.com.About CENTOGENECENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.6 billion weighted data points from approximately 570,000 patients representing over 120 different countries as of August 31, 2020.The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of August 31, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.Important Notice and Disclaimer This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020, Form 6-K containing our financial results for the three months ended March 31, 2020, filed with the SEC on June 15, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. CONTACT: Media Contact: CENTOGENE Sun Kim Chief Strategy and Investor Relations Officer firstname.lastname@example.org FTI Consulting Bridie Lawlor +1.917.929.5684 email@example.com
The report "Aircraft Interface Device Market by End-Use (Fixed Wing, Rotary Wing), Fit (Line Fit, Retrofit) Aircraft Type, Connectivity, and Region (North America, APAC, Europe, Middle East, Africa, Latin America) - Forecast to 2025", published by MarketsandMarkets™, is projected to grow from USD 167 million in 2020 to USD 311 million by 2025, at a CAGR of 13.2% from 2020 to 2025. The market is driven by various factors, such as an increase in demand for real-time aviation analytics and a growing need for situational awareness. The aircraft interface device market includes major players Collins Aerospace (US), Thales SA (France), The Boeing Company (US), Astronics Corporation (US), and Elbit Systems Ltd (Israel). These players have spread their business across various countries includes North America, Europe, Asia Pacific, Middle East, Africa, and South America. COVID-19 has impacted their businesses as well. Industry experts believe that COVID-19 could affect aircraft interface device production by 7–10% globally in 2020.
The "Potato Starch Market, Volume & Global Forecast, by Products (Modified Starch, Native Starch, Sweeteners), Region, Applications, Companies" report has been added to ResearchAndMarkets.com's offering.
Lifestyle product retailer MINISO opened its 100th post-IPO physical store this November, signaling a market expansion streak amidst industry-wide scale back and closings. The opening in Madrid is the fourth in Spain this month alone, and it is bolstered by a flurry of other European and global ribbon-cuttings numbering over 100 since the brand's IPO in mid-October. Additional store openings are planned before the end of the year.
Shift Technology, a provider of AI-native fraud detection and claims automation solutions for the global insurance industry today published its latest analysis of the fraud trends being faced across the insurance industry. In Shift Technology Fraud Insights Vol. 2: November 2020, the company focuses in on the schemes driving Fraud, Waste, and Abuse (FWA) which impact health payers around the world.
International Road Dynamics Inc. ("IRD"), a Quarterhill Inc. ("Quarterhill") company (TSX: QTRH) (OTCQX: QTRH), announced today that the Oklahoma Department of Transportation (ODOT) has authorized IRD to move forward with the installation of a VWS System. The financial terms of the contract are confidential.
In this exciting episode of Trending Today, we traveled to Louisville, KY to experience the Rugged Rodeo at the Retail Service Systems Conference. Where the best of the best gathers as one to motivate to the next level with interactive training, dynamic guest speakers and the reveal of the Rugged Entrepreneur mascot. Learn more about one of Retail Service System's industry leading franchise models, BoxDrop, as our team heads over to Dublin, OH to see how they are disrupting the mattress and furniture industry. We then head over to bioPURE headquarters in Johnson City, TN, where we got a firsthand look at how this group of Rugged Entrepreneurs are changing the standard of clean with cutting edge technology and continuing education. We end in Eustis, FL with Father Son Daughter (FSD) Hot Rod Ranch, an industry leader in selling and trading classic cars, hot rods, exotics and novelty cars.
Amesite Inc. (Nasdaq: AMST), an artificial intelligence software company providing online learning ecosystems for business, higher education, and K-12, announced today that global investor, developer and entrepreneur George Parmer has joined its Board of Directors. The appointment brings the total number of board members to seven.